Morgan Stanley Reiterates Overweight on Insmed, Maintains $41 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has reiterated an Overweight rating on Insmed (NASDAQ:INSM) and maintained a price target of $41.
August 04, 2023 | 5:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Insmed and maintained a price target of $41.
The reiteration of an Overweight rating by Morgan Stanley indicates a positive outlook for Insmed. The maintained price target of $41 suggests that the analyst believes the stock is undervalued at current levels. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100